APA (7th ed.) Citation

JF, L., KN, M., MJ, B., S, B., UA, M., JR, I., . . . HA, B. (2016). Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 27(11), 2124. https://doi.org/10.1093/annonc/mdw401

Chicago Style (17th ed.) Citation

JF, Liu, et al. "Phase I Study of Safety and Pharmacokinetics of the Anti-MUC16 Antibody-drug Conjugate DMUC5754A in Patients with Platinum-resistant Ovarian Cancer or Unresectable Pancreatic Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology 27, no. 11 (2016): 2124. https://doi.org/10.1093/annonc/mdw401.

MLA (9th ed.) Citation

JF, Liu, et al. "Phase I Study of Safety and Pharmacokinetics of the Anti-MUC16 Antibody-drug Conjugate DMUC5754A in Patients with Platinum-resistant Ovarian Cancer or Unresectable Pancreatic Cancer." Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 11, 2016, p. 2124, https://doi.org/10.1093/annonc/mdw401.